CHICAGO – The postoperative addition of nivolumab (Opdivo) to chemoradiotherapy (CRT) extended disease-free survival (DFS) in ...

NIVOPOSTOP trial data demonstrate a reduction in the risk of recurrence or death with adjuvant nivolumab combined with ...

Libtayo (cemiplimab) was cleared in 2018 for treating advanced CSCC in patients who are not candidates for curative surgery ...

Adjuvant Opdivo, cisplatin and radiotherapy improved DFS vs other treatment among those with locally advanced squamous cell ...